

Translational Support & Opportunities for UCL researchers


Institute for Women's Health Department Meeting 15th Feb 2018

Lorna Ravenhill
Translational Research Office (TRO)
Senior Business & Innovation Manager



Translational Research Office (TRO)





TRO: Accelerating translation, mapping research landscape and supporting therapeutic innovations



Translational Research Office (TRO)



 Establishing & sustaining a portfolio of funded translational projects




 Medicinal chemistry and drug discovery support to novel UCL targets



• Establish insights into UCL's translational strengths, matching to external market opportunities for strategic academic-led collaboration & innovation

AIM: Enable growth of biomedical research translation towards patient benefit







Over £50 million in grant funding for translational research



Over £7 million from industrial collaborations



Over 50 interactions with Big Pharma and SMFs



More than 5 major strategic alliances



The TRO has a Therapeutic
Acceleration Support (TAS)
fund which can help UCL
transition discovery science to
early stages of therapeutic
development

TRO: Drug Discovery Group (DDG)



Hands on support for small molecule drug discovery

- Target tractability assessment
- Development of project and medicinal chemistry strategies
 - Screening strategies, Hit discovery and validation, Hit to Lead & Lead Optimisation
- Compound design and synthesis, development of screening assays
- Coordination of external studies
 - DMPK, toxicology, pre-clinical development
- Extensive drug discovery networks (pharma, biotech, academic)
- Advice on drug discovery grant applications



Richard Angell
Head of the Drug
Discovery Group
r.angell@ucl.ac.uk

GSK, Arrow Therapeutics, AstraZeneca, co-founder ReViral



Sally Oxenford
Senior Medicinal
Chemist
s.oxenford@ucl.ac.uk

Piramed, Cellzome.



Alice Hooper

Medicinal Chemist
alice.hooper@ucl.ac.uk

Institute of Cancer Research, Sutton



Trevor Askwith
Senior Biologist
t.askwith@cl.ac.uk

Novartis, University of Sussex Drug Discovery Centre

email: r.angell@ucl.ac.uk, phone no: 0207 753 5973

address: UCL School of Pharmacy, 29-39 Brunswick Square, London https://www.ucl.ac.uk/translational-research/drug-discovery-group

TRO: Business & Innovation Group (B&IG)



Strategic support to SLMS Faculties through collaboration with stakeholders.

- 1. Intelligence gathering and due-diligence
- 2. Innovation Strategies
 - 1. Strategic support to Faculties and Divisions
 - 2. Community building (Therapeutic Innovation Network in Cell and Gene Therapy, Small Molecules, Biologics, Devices and Diagnostics)
 - 3. Public-Industry dual funding calls (Collaborate to Innovate and MRC-Proximity to Discovery fund)
 - 4. Education/enhancing translational culture
- **3. Academic-led new business development** (e.g. Discoveries CTR Portugal-UK consortium)
- 4. Establishing and managing strategic industrial partnerships'

Dr Maryam Atakhorrami Head of the Business & Innovation Group m.atakhorrami@ucl.ac.uk	Phillips Innovation, VU Amsterdam, Harvard, Upenn.
Dr Marta Ribeiro Business & Innovation Manager m.ribeiro@ucl.ac.uk	IESE Business School, Hospital Clinic Barcelona.
Dr Lorna Ravenhill Business & Innovation Manager I.ravenhill@ucl.ac.uk	Royal Holloway, Antitope, Sanger Institute.
Dr Chloe Marden Business & Innovation Manager c.marden@ucl.ac.uk	Royal Free Hospital (UCL), UCSF.

email: m.atakhorrami@ucl.ac.uk, phone no: (0)20 7679 6465 Address: Maple House, 1st Floor 1A | 149 Tottenham Court Road

TRO: Translational Research Group (TRG)



Support for translation across all therapeutic areas & modalities, from target development to clinical trials.

- Identifying opportunities for translation
- Scoping out project progression paths to impact
- Assisting PIs in securing funding and maximising outputs
- Providing overarching project support
 - Advising on project planning and milestones
 - Identifying and contracting with service providers

E-mail: p.tranter@ucl.ac.uk Phone: 020 7679 6775

Address: Maple House 1A, First Floor, 149 Tottenham Court Road, London. W1T 7JA

Website: www.ucl.ac.uk/translational-research/about-trg

	Head of the TRG		
	Pamela Tranter p.tranter@ucl.ac.uk	Novartis, Ciba-Geigy, Royal Free NHS Trust	
	Translational Research Managers		
	Alethea Cope a.cope@ucl.ac.uk	Imperial College, St George's, Porton Down, Wolfson UCL	
9	Dan Fullen d.fullen@ucl.ac.uk	hVIVO, Covance, NIBSC, Unilever	
	Ged Corbett g.corbett@ucl.ac.uk	MRC-LMB, Paradigm Therapeutics, Takeda	
	Joanna Davidge joanna.davidge@ucl.ac.uk	Pfizer, MRC, Royal Free NHS Foundation Trust	
	Leanne Partington I.partington@ucl.ac.uk	Dstl, GSK, Novartis, CGT Catapult	
	Martin Anyim m.anyim@ucl.ac.uk	NIHR, Barts & The London NHS Trust	
	Simon Eaglestone s.eaglestone@ucl.ac.uk	Pfizer, QMUL, Barts Health NHS Trust	

Translating UCL Science



University College London Hospitals / UCL BRC

UCL Therapeutic Innovation Network / TREACC

TRO

Translational Research Office

- Translational Research
- Industrial partnerships
- Drug discovery
- Grant application

TINs

Therapeutic
Innovation Networks

- Cell & Gene Therapy
- Small Molecules
- Biologics
- Devices

JRO

Joint Research Office

- Research management
- Research Governance
- Contracting

UCLB

UCL Business

- Tech Transfer
- IP, licensing
- Asset management


Therapeutic Acceleration Support Fund

University College London Hospitals Biomedical Research Centre Life changing medicine through translational research and innovation



Accessing Translational Research Funding





'Internal' Research Funding Opportunities





Therapeutic Acceleration
Support Fund (TAS)

MRC Confidence in Concept Fund at UCL

TIF (2010-2016)

Internally managed funding from WT and the BRCs

CiC (2013-2016)

- MRC funding for flexible early translational research
- ➤ Leveraged an additional £15M follow-on funding
- 3 projects have been licensed into two UCL spin outs
 - Autulus Tx (£70m raised in Series A and series B)
 - Orchard Tx (£21m raised in Series A)

https://www.ucl.ac.uk/translational-research/funding-opps/internal-funding

TAS (2017-)

- Internally managed funding from MRC, WT and the BRCs
- 2 calls per year; 12 month projects, <£75k each
- Call 1 (Mar'17) 12 of 21 proposals awarded (£722K total)
- Call 2 (Sep'17) 7 of 24 proposals awarded (£500K total)

 NB. 4 of 7 awarded were resubmitted/follow-ons
- > Call 3 (Opens 19th March 2018)

Proximity to Discovery Secondments

- MRC-funding promoting KE to companies, social enterprises, charities and other non-academic organisations
- £30-55k each, 3-6 months
- ➤ 18 awarded through SLMS since 2016 (£350K total)
- Call now open

Examples of TRO internal funding for IfWH Projects



Confidence in Concept (call 3 2015)



Project – Enhanced gene therapy of haematological disorders with the next-generation LTR1 lentiviral vector.

TRO support – Joanna Davidge

Dr Simon Waddington

Confidence in Concept (call 4 2016)



Project – Demonstrating Functional Haematopoiesis of Human Gene Corrected Amniotic Fluid Derived Stem Cells For Therapeutic Purposes.

Prof Anna David

TRO support – Joanna Davidge

TINs

Therapeutic Innovation Networks

- Cell & Gene Therapy
- Small Molecules
- Biologics
- Devices

Examples of TRO support for IfWH Projects



Translational Research Management



Dr Joanne Ng & Simon Waddington

Project -

Gene Therapy for DAT deficiency

Award -

MRC DPFS (2018)

TRO support –

Joanna Davidge

Business & Innovation Support



Prof Usha Menon

Project -

UKCTOCS business case and

LPS Wellcome Trust Longitudinal Population

Study Grant application


TRO support -


Maryam Atakhorrami and Althea Cope

Industrial Research Collaborations with IfWH



Industrial Research Collaborations





IfWH Industrial Collaborations 2010 – 2016



10 Industrial Partners

11
Industrial
Research
Collaborations


£3.2m Total Award Value

Clinical Trial Involvement

- IfWH had the **3rd largest industry income** for research collaborations across Faculty
- **7** Research Projects and **2** Studentships
- 2 projects had clinical trial involvement including biobank
 UKCTOCS Biobank and neonatal encephalopathy
- Top industrial funders are Abcodia UK and Chiesi S.p.a

TRO: Support & opportunities for biomedical research translation towards patient benefit







Thank You



